Pharma Horizons: Cell and Gene Therapy

This report delves into the current key trends in cell and gene therapy impacting the pharmaceutical sector today. Inside, articles explore current key topics including manufacturing, drug delivery and development.

Stay up to date with the latest advances in the cell and gene therapy sector with articles that include:

• Expert insight into current industry developments and key obstacles including market uncertainty, supply chain, advancing innovations in technology such as AI and more
• How the major developments in cell and gene therapy in 2026 could impact the broader pharma industry in the next few years
• How biotechs can navigate the complex regulatory landscape as ATMP development in Europe moves toward maturity in 2026
• The potential of T-cell engagers and the main obstacles hindering their development, including potential solutions
• Advancing the potential of delivering T-cell therapy in-vivo using DARPin-conjugated LNPs
• How innovating lentiviral vectors using engineered VSV-G could offer a next-generation in vivo CAR-T approach, addressing manufacturing bottlenecks to enable scalable CAR-T delivery for a broader range of indications
• What to expect on the manufacturing, regulation and drug development front in 2026.

Register now to access this exclusive content as we discover some of the main trends and opportunities in cell and gene therapy, with insight from experts including:

• Michela Palmisano, Senior Cell & Gene Therapy Consultant, Qualified Person and Simona Guidi, Associate Director Cell & Gene Therapy, ProPharma
• Adam Janvier, Head of Cell Therapy, eXmoor Pharma
• Alistair Henry, Chief Scientific Officer, UCB
• Dr Stephen Russell, Co-founder and CEO, Vyriad
• Ying Tam, Chief Scientific Officer, Acuitas Therapeutics
• Brian Culley, CEO, Lineage Cell Therapeutics
• Joseph Egan, Bioprocess Modelling Engineer, Teesside University
• Ibon Garitaranandia, Chief Scientific Officer, CellProThera

Access the full report today >>